Home CUSTOMERS Neoplasma Ahead of print Neoplasma Vol.67, No.6, p.1373–1383, 2020

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.67, No.6, p.1373–1383, 2020

Title: Association of triple positivity with prognostic parameters and overall survival in a population-based study of 6,122 HER2-positive breast cancer patients: analysis of real-world clinical practice based on a research database
Author: I. KOLAROVA, J. VANASEK, M. DOLEZEL, J. STUK, A. HLAVKA, L. DUSEK, B. MELICHAR, T. BÜCHLE, A. RYSKA, J. PRAUSOVA, K. PETRAKOVA, P. TESAROVA, J. PETERA, M. VOSMIK, K. HORACKOVA, J. JARKOVSKY

Abstract: Triple-positive breast cancer (TPBC), i.e. HER2-positive (HER2+) and hormone receptors-positive breast cancer, is a specific subgroup of breast cancers. TPBC biology is characterized by strong mutual interactions between signaling pathways stimulated by estrogens and HER2 amplification. The present study aims to carry out a population-based analysis of treatment outcomes in a cohort of hormone receptor (HR) positive and negative breast cancer patients who were treated with anti-HER2 therapy in the Czech Republic. The BREAST research database was used as the data source for this retrospective analysis. The database covers approximately 95% of breast cancer patients treated with targeted therapies in the Czech Republic. The analysis included 6,122 HER2-positive patients. The patients were divided into two groups, based on estrogen receptor (ER) or progesterone receptor (PR) positivity: hormone receptor negative (HR-) patients had both ER- and PR-negative tumors (n = 2,518), unlike positive (HR+) patients (n = 3,604). HR+ patients were more often diagnosed premenopausal at the time of diagnosis, presented more often at stage I or II and their tumors were less commonly poorly differentiated. The overall survival (OS) was significantly higher in subgroups of HR+ patients according to treatment setting. When evaluated by stages, significantly higher OS was observed in HR+ patients diagnosed at stages II, III, and IV and regardless of tumor grade.

Keywords: breast cancer, triple positive, HER2-positive, hormone receptors, trastuzumab, overall survival
Published online: 01-Jul-2020
Year: 2020, Volume: 67, Issue: 6 Page From: 1373, Page To: 1383
doi:10.4149/neo_2020_191023N1080


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.